Radiotherapy, 6, 68, 72, 76–82, 99, 130–31, 136–39, 148, 189, 192, 194 Rare cancers, 68, 87, 90, 99, 108, 190, 194 Risk of cancer development, 4, 21, 38–53, 158, 194 S Side effects, 111, 115, 117, 119, 123, 125–26, 129, 132, 138, 188, 194 Skin cancer, 6, 38, 47–48, 52, 59, 108–9, 192, 194 Smoking, 3–5, 12, 20–21, 30, 32, 38–39, 41, 44, 46, 136, 138, 142, 159 Somatic mutations, 4, 29–30, 190, 194 Survivorship, 12, 15, 18–19, 37, 71, 134, 139, 162, 194 T Targeted therapeutics, 6, 10, 14, 20, 23, 76, 83–85, 87, 91, 95, 100, 103, 107–8 Targeted therapies, 30, 32, 76–77, 85, 89, 93, 104, 130–31, 157, 184, 188, 192 T-cell therapies, 7, 10, 99, 101, 109, 114–17, 125–26, 129, 150–51, 165, 194 Technologies, 8, 11, 25, 29, 75, 140, 142, 155, 158, 190, 194 Telemedicine, 64, 75, 142, 147 Therapeutic antibodies, 101–2, 120, 124–25 Tobacco, 39–40, 47, 159, 182 Treatment resistance, 31–32, 87, 90, 190, 194 Tumor heterogeneity, 8, 32, 34, 146–47, 194 U Underserved populations, 3, 5, 15, 18, 38, 44, 53, 70, 75, 83, 158 USPSTF (U.S. Preventive Services Task Force), 5, 11, 21, 49, 54, 56–62, 149, 173, 190, 194 Uterine cancer, 3, 11, 18, 20, 194 Vvaccines, 7, 49–50, 117, 128, 146, 148, 150, 166, 190, 194 Index AACR Cancer Progress Report 2023 195
RkJQdWJsaXNoZXIy NTkzMzk=